Dividends are payments that companies make to their shareholders out of their profits. These payments usually happen regularly, like every quarter. This means they can offer a reliable income stream and are often seen as a sign that a company is doing well. You typically find dividend stocks in sectors like utilities, real estate, consumer goods, and others.There’s a lot to like about investing in dividend stocks. They provide a way to make money in two ways; you get the regular dividend payments, and you c ...

blackred Most investors by now can appreciate the opportunity that AI represents for society and the economy, and stocks like Nvidia (NVDA), Super Micro Computer (SMCI) and Dell Technologies (DELL) that are leading this revolution have been rewarded with rich valuations. With so many investor eyeballs and fingers on the buy button whenever there are dips in those names, it's hard not to wonder if we are in another sort of bubble. This reminds of the tech bubble in 2000, during which Cisco (CSCO) surpass ...

Thomas Pajot/iStock via Getty Images Introduction As individual investors, we have to take what the market gives us. We don't get to decide when stocks are on sale, whether they are overvalued, or what the macroeconomic and regulatory environment will be. All we can do is assess the current value and what the value of a business might be in the future. Historically, during most time periods, there has been some group of assets that were reasonably undervalued investors could put their money in for a good ...

The pharmaceutical market is a critical part of the healthcare industry. It contributes largely to research, development, production and distribution of important life-saving vaccines and medications.As the global healthcare system, quality of life and average life expectancy continue to improve, the need for research and development of these critical medications and treatments are also on the rise.A large number of healthcare companies rely on trials, which makes it difficult to predict the company’s futur ...

GERMANY - 2024/03/03: In this photo illustration, the Bristol-Myers Squibb Company logo is seen ... [+] displayed on a tablet. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesBristol Myers Squibb stock (NYSE: BMY) currently trades at $42 per share, 47% below its pre-inflation shock high of $80 seen in June 2022. In contrast, its peer – Merck stock – is up 56% over this period. BMY stock was trading at $77 in early June 2022, just before ...

文章核心观点 - 美国FDA批准布里斯托-迈尔斯-斯奎布(BMY)的肿瘤药物Krazati(adagrasib)适应症扩大,可用于治疗KRASG12C突变的局部晚期或转移性结直肠癌(CRC)成人患者[1][2][3][4][5][6] - Krazati联合Erbitux(cetuximab)治疗KRASG12C突变的CRC患者,在临床试验中显示客观缓解率(ORR)为34%,中位缓解持续时间(DOR)为5.8个月[4] - CRC中KRASG12C突变约占3-4%,这类患者难以治疗,Krazati的批准为他们提供了新的治疗选择[6] - Krazati还获得了治疗KRASG12C突变的局部晚期或转移性非小细胞肺癌(NSCLC)的加速批准[7] - BMY正在评估Krazati单药及联合其他抗肿瘤疗法治疗KRASG12C突变的晚期实体瘤,包括NSCLC和CRC[8] 公司相关 - BMY通过收购Mirati Therapeutics在2024年1月获得了Krazati[6] - BMY还获得了其他肺癌药物Augtyro(repotrectinib)和CAR-T疗法Abecma、Breyanzi的适应症扩大批准,以及Reblozyl(luspatercept)在欧洲的适应症扩大批准[10][11][13] - BMY目前股价较年初下跌18.3%,低于行业下跌5.9%[8] - BMY正努力拓展新产品组合,以应对Revlimid和Eliquis面临的仿制药挑战[9] 行业相关 - KRASG12C突变在CRC中约占3-4%,这类患者难以治疗,Krazati的批准为他们提供了新的治疗选择[6] - FDA给予Krazati加速批准,批准依据是ORR和DOR结果,但需要在后续试验中验证临床获益[3] - 行业内其他表现较好的公司还有Ligand Pharmaceuticals、ALX Oncology Holdings和Minerva Neurosciences[15]

Income-oriented investors love finding dividend stocks to buy now. That’s particularly true when those stocks are on sale, as many continue to be. However, heading into summer, many things make risk-averse investors cautious about buying equities.  Still, if the CME Group FedWatch Tool is correct, the next direction that interest rates will move is down. And that move may happen as early as September. At that time, the belief is that investors will benefit as a wider range of stocks become buyable. And as i ...

The pharmaceutical industry giants offer reliable profit growth and above-average dividend yields.Investors looking for high-yield dividend stocks to buy now should turn their attention toward the healthcare sector: Three relatively reliable drugmakers are trading near their 52-week lows.Their stock prices may have been beaten down, but it's more than likely that better days are ahead. Here's how these stocks could produce heaps of passive income for patient investors who buy now.1. PfizerShares of Pfizer ( ...

Investors continue to look for the market to broaden before jumping in. They may be waiting awhile. However, if you have a long-term view of the market, it’s a good time to look for some Warren Buffett stocks to buy now.A Warren Buffett stock is a stock owned by Buffett’s hedge fund, Berkshire Hathaway (NYSE:BRK-A, NYSE:BRK-B). Each stock highlights one or more of the investment principles associated with Buffett himself such as stable revenue and earnings, companies that show a competitive advantage (e.g. ...

文章核心观点 - 尽管部分医疗保健股票在过去一年内下跌超过25%,但它们的股息分配仍在稳步上升[1][2][3] - 辉瑞、布里斯托尔-迈尔斯-斯奎布和CVS Health等公司的股价下跌,但它们的股息计划仍在持续增长[3] 辉瑞 - 辉瑞股价下跌约31%,主要是因为其新冠疫苗和治疗药物销售大幅下降[4][5] - 尽管销售下滑,但辉瑞自2009年以来一直稳步提高股息,目前股息收益率达6.1%[5] - 辉瑞预计未来几年这些药品销售将进一步下降,但股息有足够的支撑[6] - 剔除新冠相关产品,辉瑞第一季度销售同比增长11%,未来有望恢复增长[7] 布里斯托尔-迈尔斯-斯奎布 - 布里斯托尔-迈尔斯-斯奎布股价下跌约35%,目前股息收益率达5.7%[8] - 公司调低了业绩指引,主要是由于完成了140亿美元收购卡鲁纳治疗公司[9][10] - 收购卡鲁纳可能带来长期收益,因其新药物KarXT有望成为首个不直接阻断多巴胺受体的精神分裂症新药[11] - 目前公司股价估值较低,长期持有有望获得超越大盘的收益[12] CVS Health - CVS Health拥有零售药店、药品福利管理和医疗保险等多元化业务[13] - 公司股价下跌约27%,目前股息收益率达4.4%,过去10年股息增长142%[14][15] - 近期股价下跌主要是由于Medicare Advantage业务的服务使用率和报销率低于预期[16] - 但整体医疗支出增长趋势强劲,有望支撑CVS Health未来10年持续大幅提高股息[17][18]